Holen Sie sich die Stockscreener-App
4.80
0.42%
0.02
Handel nachbörslich:
4.87
0.07
+1.46%
Schlusskurs vom Vortag:
$4.78
Offen:
$4.8035
24-Stunden-Volumen:
10,290
Relative Volume:
0.01
Marktkapitalisierung:
$9.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-5.73M
KGV:
-0.7328
EPS:
-6.55
Netto-Cashflow:
$-4.13M
1W Leistung:
-0.41%
1M Leistung:
-9.77%
6M Leistung:
+98.35%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.73
$4.87
1-Wochen-Bereich:
$4.65
$5.37
52-Wochen-Spanne:
$1.62
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Firmenname
Dogwood Therapeutics Inc
Sektor
Branche
Telefon
(866) 620-8655
Adresse
44 MILTON AVENUE, ALPHARETTA
Vergleichen Sie DWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
4.80 | 9.42M | 0 | -5.73M | -4.13M | -6.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference - GlobeNewswire
Emerging Biotech Dogwood Therapeutics Reveals Growth Strategy at Sidoti Small-Cap Conference - Stock Titan
Dogwood (DWTX) Pursues $150M Mixed Securities Offering | DWTX St - GuruFocus
Dogwood (DWTX) Pursues $150M Mixed Securities Offering | DWTX Stock News - GuruFocus
DWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway… - Yahoo Finance
DWTX: Dogwood Therapeutics Expands Research on Pain Management | - GuruFocus
Dogwood Therapeutics Reports Progress in Pain Treatment Trials - TipRanks
Dogwood Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Dogwood Therapeutics Announces First Quarter 2025 Financial Results - The Manila Times
Dogwood Therapeutics Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView
Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
Exclusive Access: Dogwood Therapeutics CEO Hosts Private Investor Meetings at Prestigious NYC Conference - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Upgraded at HC Wainwright - Defense World
HC Wainwright & Co. Upgrades Dogwood Therapeutics (DWTX) - Nasdaq
HC Wainwright Upgrades Dogwood Therapeutics to Buy From Neutral - marketscreener.com
Financial Metrics Unveiled: Dogwood Therapeutics Inc (DWTX)’s Key Ratios in the Spotlight - DWinneX
Best Biotech Stocks To Watch Today – April 21st - Defense World
Dogwood Therapeutics Inc (NASDAQ: DWTX) Has Been Trading Down. What Are The Prospects For The Future? - Stocksregister
You might want to take a look at Dogwood Therapeutics Inc (DWTX) now - Sete News
You Should Read This Analysis Before Investing in Dogwood Therapeutics Inc (NASDAQ:DWTX) - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Dogwood Therapeutics (DWTX) Begins Phase 2b Trial for Halneuron - GuruFocus
Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance - GuruFocus
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance with Equit - GuruFocus
Dogwood Therapeutics regains Nasdaq compliance By Investing.com - Investing.com South Africa
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance - marketscreener.com
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewswire
Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Sodium Channel Blockers Clinical Trial Pipeline Accelerates - GlobeNewswire
DWTX: Interim Data for Phase 2b Trial in 4Q25… - Yahoo Finance
Dogwood Therapeutics regains compliance with Nasdaq - MSN
DWTX: Interim Data for Phase 2b Trial in 4Q25 - Research Tree
Dogwood Therapeutics Announces Nasdaq Compliance Regained - Nasdaq
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire
Dogwood Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Dogwood Therapeutics, Inc. SEC 10-K Report - TradingView
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Dogwood Strengthens Balance Sheet with $24M Capital Actions as Halneuron Trial Progresses - Stock Titan
Dogwood Therapeutics Inc. (DWTX) reports earnings - Quartz
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain By Investing.com - Investing.com South Africa
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet… - Zacks Small Cap Research
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain - Marketscreener.com
Dogwood Therapeutics begins Phase 2b trial for neuropathic pain - Investing.com
Dogwood Therapeutics Announces Dosing of First Patient in - GlobeNewswire
Revolutionary Non-Addictive Pain Treatment Enters Critical Phase 2b Trial for Cancer Patients - StockTitan
Finanzdaten der Dogwood Therapeutics Inc-Aktie (DWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):